Ascendis Pharma A/S (ASND)Healthcare | Biotechnology | Hellerup, Denmark | NasdaqGS
223.21 USD
-3.79
(-1.670%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
After hours: 223.21 |
Hot Take ↕ | Oct. 10, 2026, 4:53 a.m. EDT
Ascendis Pharma is a standout compounder with a nine-year track record of massive gains and a balance sheet that supports aggressive R&D without debt distress. Despite the stock trading below its 50-day average, the options chain reveals a bullish consensus targeting the 250 level, and the fundamentals justify a premium valuation. Investors seeking income will find no yield here, but those focused on growth are positioned for a multi-year winner that is currently taking a breather. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.041700 |
| AutoARIMA | 0.041700 |
| MSTL | 0.047429 |
| AutoTheta | 0.076879 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 38% |
| H-stat | 9.67 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.507 |
| Excess Kurtosis | -0.45 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 31.331 |
| Revenue per Share | 16.889 |
| Market Cap | 14,688,030,720 |
| Trailing P/E | 17.10 |
| Forward P/E | 20.72 |
| Profit Margins | 70.84% |
| Website | https://ascendispharma.com |
As of Oct. 10, 2026, 4:53 a.m. EDT: Call buyers are establishing a heavy wall at the 250 strike, while put sellers are defending the 220-230 zone. Implied volatility is significantly higher at deep out-of-the-money strikes, indicating speculation on a large move rather than a slow drift.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.08763361 |
| Address1 | Tuborg Boulevard 12 |
| All Time High | 282.15 |
| All Time Low | 11.92 |
| Ask | 242.01 |
| Ask Size | 2 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 821,810 |
| Average Daily Volume3 Month | 670,710 |
| Average Volume | 670,710 |
| Average Volume10Days | 821,810 |
| Bid | 208.1 |
| Bid Size | 2 |
| Book Value | 24.620249 |
| City | Hellerup |
| Compensation As Of Epoch Date | 1,640,908,800 |
| Country | Denmark |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 223.21 |
| Current Ratio | 2.991 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 228.91 |
| Day Low | 222.215 |
| Debt To Equity | 31.331 |
| Display Name | Ascendis Pharma |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,770,845,400 |
| Earnings Call Timestamp Start | 1,770,845,400 |
| Earnings Timestamp End | 1,777,579,200 |
| Earnings Timestamp Start | 1,777,579,200 |
| Ebitda | 263,454,000 |
| Ebitda Margins | 0.25162 |
| Enterprise To Ebitda | 54.267 |
| Enterprise To Revenue | 13.655 |
| Enterprise Value | 14,296,748,032 |
| Eps Current Year | 12.7916 |
| Eps Forward | 10.772067 |
| Eps Trailing Twelve Months | 13.05 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 245.7501 |
| Fifty Day Average Change | -22.5401 |
| Fifty Day Average Change Percent | -0.0917196 |
| Fifty Two Week Change Percent | 8.763361 |
| Fifty Two Week High | 282.15 |
| Fifty Two Week High Change | -58.939987 |
| Fifty Two Week High Change Percent | -0.20889594 |
| Fifty Two Week Low | 186.054 |
| Fifty Two Week Low Change | 37.156006 |
| Fifty Two Week Low Change Percent | 0.1997055 |
| Fifty Two Week Range | 186.054 - 282.15 |
| Financial Currency | EUR |
| First Trade Date Milliseconds | 1,422,455,400,000 |
| Float Shares | 65,641,104 |
| Forward Eps | 10.772067 |
| Forward P E | 20.721186 |
| Free Cashflow | 12,771,750 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 1,189 |
| Fullday Change | -3.7899933 |
| Fullday Change Percent | -1.6696006 |
| Fullday Price | 223.21 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.91296995 |
| Gross Profits | 955,894,976 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00769 |
| Held Percent Institutions | 1.02957 |
| Implied Shares Outstanding | 65,803,642 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark. |
| Long Name | Ascendis Pharma A/S |
| Market | us_market |
| Market Cap | 14,688,030,720 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_39510693 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 741,758,016 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 14,678,243,348 |
| Number Of Analyst Opinions | 20 |
| Open | 225.99 |
| Operating Cashflow | 349,512,000 |
| Operating Margins | 0.64979 |
| Payout Ratio | 0.0 |
| Phone | 45 70 22 22 44 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 223.21 |
| Post Market Time | 1,791,921,643 |
| Previous Close | 227.0 |
| Price Eps Current Year | 17.449734 |
| Price Hint | 2 |
| Price To Book | 9.066115 |
| Price To Sales Trailing12 Months | 14.028414 |
| Profit Margins | 0.70845 |
| Quick Ratio | 2.229 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.25 |
| Region | US |
| Regular Market Change | -3.78999 |
| Regular Market Change Percent | -1.6696 |
| Regular Market Day High | 228.91 |
| Regular Market Day Low | 222.215 |
| Regular Market Day Range | 222.215 - 228.91 |
| Regular Market Open | 225.99 |
| Regular Market Previous Close | 227.0 |
| Regular Market Price | 223.21 |
| Regular Market Time | 1,791,921,601 |
| Regular Market Volume | 592,240 |
| Return On Assets | 0.09583 |
| Return On Equity | 1.18784 |
| Revenue Growth | 1.147 |
| Revenue Per Share | 16.889 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 65,803,642 |
| Shares Percent Shares Out | 0.0529 |
| Shares Short | 3,484,067 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 4,203,221 |
| Short Name | Ascendis Pharma A/S |
| Short Percent Of Float | 0.0627 |
| Short Ratio | 3.87 |
| Source Interval | 15 |
| Symbol | ASND |
| Target High Price | 349.90805 |
| Target Low Price | 262.24936 |
| Target Mean Price | 307.5568 |
| Target Median Price | 312.41983 |
| Total Cash | 812,259,968 |
| Total Cash Per Share | 12.368 |
| Total Debt | 450,073,984 |
| Total Revenue | 1,047,020,032 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 13.05 |
| Trailing P E | 17.104216 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 236.20575 |
| Two Hundred Day Average Change | -12.995743 |
| Two Hundred Day Average Change Percent | -0.05501874 |
| Type Disp | Equity |
| Volume | 592,240 |
| Website | https://ascendispharma.com |
| Zip | 2,900 |